Dr. Horwitz Discusses the Results of the ECHELON-2 Study

Steven M. Horwitz, MD
Published: Wednesday, Dec 12, 2018



Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the ECHELON-2 study in patients with CD30+ peripheral T-cell lymphomas (PTCL).

In this phase III study of patients with CD30-expressing PTCL, the addition of brentuximab vedotin (Adcetris) to chemotherapy led to a clinically meaningful improvement in progression-free survival (PFS) and overall survival. The primary endpoint was PFS per blinded independent central review.

Findings showed a 29% reduction in the risk of disease progression, a 34% reduction in the risk of death, and a 3-year PFS rate of 57.1% versus 44% with CHOP. PFS benefit was generally observed across all patient subgroups, most notably in patients with ALK-positive systemic anaplastic large cell lymphoma.

Brentuximab vedotin was approved by the FDA in November 2018 for the frontline treatment of patients with CD30-expressing PTCL in combination with chemotherapy. Previously, the frontline standard of care for patients with PTCL has been CHOP or a CHOP-like regimen with curative intent.
SELECTED
LANGUAGE


Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the ECHELON-2 study in patients with CD30+ peripheral T-cell lymphomas (PTCL).

In this phase III study of patients with CD30-expressing PTCL, the addition of brentuximab vedotin (Adcetris) to chemotherapy led to a clinically meaningful improvement in progression-free survival (PFS) and overall survival. The primary endpoint was PFS per blinded independent central review.

Findings showed a 29% reduction in the risk of disease progression, a 34% reduction in the risk of death, and a 3-year PFS rate of 57.1% versus 44% with CHOP. PFS benefit was generally observed across all patient subgroups, most notably in patients with ALK-positive systemic anaplastic large cell lymphoma.

Brentuximab vedotin was approved by the FDA in November 2018 for the frontline treatment of patients with CD30-expressing PTCL in combination with chemotherapy. Previously, the frontline standard of care for patients with PTCL has been CHOP or a CHOP-like regimen with curative intent.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x